Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 3Stomach Neoplasms 1Rectal Neoplasms 1Esophageal Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Adenocarcinoma Of Esophagus 1

Interventions

Fluorouracil 5Radiotherapy 3Paclitaxel 3Leucovorin 3Endoscopy 3Cisplatin 3Oxaliplatin 2Neoadjuvant Therapy 2Endoscopy, Digestive System 2Endoscopic Mucosal Resection 2Carboplatin 2tremelimumab 1rucaparib 1rubitecan 1durvalumab 1Taxes 1Surveys and Questionnaires 1Ramucirumab 1Radiation 1Positron Emission Tomography Computed Tomography 1Nivolumab 1Microarray Analysis 1Magnetic Resonance Imaging 1Irinotecan 1High-Throughput Screening Assays 1Genetic Linkage 1Epirubicin 1Dynamic Contrast Enhanced Magnetic Resonance Imaging 1Drug Therapy 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Adenocarcinoma Of Esophagus × rubitecan × Clear all
NCT00005876 2013-12-04

Nitrocamptothecin in Treating Patients With Locally Advanced or Metastatic Stomach Cancer That Cannot Be Removed During Surgery

National Cancer Institute (NCI)

Phase 2 Unknown
Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡